{"id":"https://openalex.org/W2012298247","doi":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","title":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study","display_name":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study","alternate_titles":[],"publication_year":2009,"publication_date":"2009-04-11","ids":{"openalex":"https://openalex.org/W2012298247","doi":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","mag":"2012298247","pmid":"https://pubmed.ncbi.nlm.nih.gov/19466963"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2133.2009.09208.x","doi":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2012298247"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110221324","display_name":"Mohamed El\u2010Darouti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145487455","display_name":"Cairo University","ror":"https://ror.org/03q21mh05","country_code":"EG","type":"education","lineage":["https://openalex.org/I145487455"]}],"countries":["EG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. El-Darouti","raw_affiliation_strings":["Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt","Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt","institution_ids":["https://openalex.org/I145487455"]},{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075886162","display_name":"Salonas A. Marzouk","orcid":"https://orcid.org/0000-0002-7658-188X","observed_orcids":["https://orcid.org/0000-0002-7658-188X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Marzouk","raw_affiliation_strings":["Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050907443","display_name":"Rania Mounir Abdel Hay","orcid":"https://orcid.org/0000-0002-3280-0796","observed_orcids":["https://orcid.org/0000-0002-3280-0796"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"R. Abdel Hay","raw_affiliation_strings":["Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113629809","display_name":"Amira El Tawdy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. El Tawdy","raw_affiliation_strings":["Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108079615","display_name":"MarwaM Fawzy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Fawzy","raw_affiliation_strings":["Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113577360","display_name":"Tahra M. Leheta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Leheta","raw_affiliation_strings":["Departments of Dermatology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006602039","display_name":"H. A. Gammaz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Gammaz","raw_affiliation_strings":["Department of Dermatology, Al Hod Al Marsoud Hospital, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Al Hod Al Marsoud Hospital, Cairo, Egypt","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015445234","display_name":"N. Al Gendy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145487455","display_name":"Cairo University","ror":"https://ror.org/03q21mh05","country_code":"EG","type":"education","lineage":["https://openalex.org/I145487455"]}],"countries":["EG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Al Gendy","raw_affiliation_strings":["Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt","institution_ids":["https://openalex.org/I145487455"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5050907443"],"corresponding_institution_ids":[],"apc_list":{"value":3731,"currency":"GBP","value_usd":4920},"apc_paid":null,"fwci":4.1282,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.93249312,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"161","issue":"2","first_page":"313","last_page":"319"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11730","display_name":"Autoimmune Bullous Skin Diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11730","display_name":"Autoimmune Bullous Skin Diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11650","display_name":"Skin and Cellular Biology Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pemphigus-vulgaris","display_name":"pemphigus vulgaris","score":1.0},{"id":"https://openalex.org/keywords/sulfasalazine","display_name":"sulfasalazine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pentoxifylline","display_name":"pentoxifylline","score":1.0},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8159999847412109},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.925000011920929},{"id":"https://openalex.org/keywords/anti-tnf-drugs","display_name":"anti-TNF drugs","score":0.8220000267028809},{"id":"https://openalex.org/keywords/low-cost-drugs","display_name":"low-cost drugs","score":0.6759999990463257},{"id":"https://openalex.org/keywords/autoimmune-blistering-disease","display_name":"autoimmune blistering disease","score":0.8299999833106995},{"id":"https://openalex.org/keywords/acantholysis","display_name":"acantholysis","score":0.8259999752044678},{"id":"https://openalex.org/keywords/serum-tnf-alpha-levels","display_name":"serum TNF-\u03b1 levels","score":0.8119999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9314758777618408},{"id":"https://openalex.org/C2780404050","wikidata":"https://www.wikidata.org/wiki/Q416331","display_name":"Pentoxifylline","level":2,"score":0.7837258577346802},{"id":"https://openalex.org/C2780684067","wikidata":"https://www.wikidata.org/wiki/Q415794","display_name":"Acantholysis","level":4,"score":0.647724449634552},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6320670247077942},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6093078255653381},{"id":"https://openalex.org/C2779383735","wikidata":"https://www.wikidata.org/wiki/Q420035","display_name":"Sulfasalazine","level":4,"score":0.589668333530426},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5872572064399719},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5702189207077026},{"id":"https://openalex.org/C2776760755","wikidata":"https://www.wikidata.org/wiki/Q18939","display_name":"Azathioprine","level":3,"score":0.5230294466018677},{"id":"https://openalex.org/C2781327288","wikidata":"https://www.wikidata.org/wiki/Q1483214","display_name":"Pemphigus","level":2,"score":0.5181721448898315},{"id":"https://openalex.org/C2781313415","wikidata":"https://www.wikidata.org/wiki/Q3899001","display_name":"Pemphigus vulgaris","level":2,"score":0.5174051523208618},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.5043755769729614},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4925532937049866},{"id":"https://openalex.org/C163764329","wikidata":"https://www.wikidata.org/wiki/Q785022","display_name":"Autoantibody","level":3,"score":0.3831457793712616},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36532777547836304},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.15104210376739502},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.14154264330863953},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1174149215221405},{"id":"https://openalex.org/C2780479503","wikidata":"https://www.wikidata.org/wiki/Q1477","display_name":"Ulcerative colitis","level":3,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004534","descriptor_name":"Egypt","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010392","descriptor_name":"Pemphigus","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010392","descriptor_name":"Pemphigus","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010392","descriptor_name":"Pemphigus","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010431","descriptor_name":"Pentoxifylline","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D010431","descriptor_name":"Pentoxifylline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010726","descriptor_name":"Phosphodiesterase Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D010726","descriptor_name":"Phosphodiesterase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012460","descriptor_name":"Sulfasalazine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D012460","descriptor_name":"Sulfasalazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013256","descriptor_name":"Steroids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2133.2009.09208.x","doi":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2009.09208.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:19466963","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19466963","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of dermatology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W15551718","https://openalex.org/W1513409030","https://openalex.org/W1898041135","https://openalex.org/W1904294627","https://openalex.org/W1970729056","https://openalex.org/W1993655313","https://openalex.org/W2010238643","https://openalex.org/W2015215846","https://openalex.org/W2017349100","https://openalex.org/W2022776197","https://openalex.org/W2029599724","https://openalex.org/W2031680195","https://openalex.org/W2033064334","https://openalex.org/W2043490975","https://openalex.org/W2044054951","https://openalex.org/W2050679100","https://openalex.org/W2072199622","https://openalex.org/W2074088798","https://openalex.org/W2079366822","https://openalex.org/W2081963649","https://openalex.org/W2094136265","https://openalex.org/W2122323804","https://openalex.org/W2125566475","https://openalex.org/W2144825611","https://openalex.org/W2159782604","https://openalex.org/W2162597598","https://openalex.org/W2171068757","https://openalex.org/W2188677386","https://openalex.org/W2331176038","https://openalex.org/W2417256524","https://openalex.org/W2436358005"],"related_works":["https://openalex.org/W2299323062","https://openalex.org/W2145128370","https://openalex.org/W4390904734","https://openalex.org/W1916141651","https://openalex.org/W1984781984","https://openalex.org/W1999726300","https://openalex.org/W2064664321","https://openalex.org/W2101255677","https://openalex.org/W2177188027","https://openalex.org/W2052575195"],"abstract_inverted_index":{"BACKGROUND:":[0],"Pemphigus":[1],"vulgaris":[2],"(PV)":[3],"represents":[4],"a":[5,30,139,171,200,231],"potentially":[6],"life-threatening":[7],"autoimmune":[8],"blistering":[9],"disease":[10],"in":[11,33,116,124,159,165,175,181,183,189,204,206,212,225,237],"which":[12],"IgG":[13],"autoantibodies":[14],"are":[15],"directed":[16],"against":[17],"cell-cell":[18],"adhesion":[19],"molecules.":[20],"Tumour":[21],"necrosis":[22],"factor":[23],"(TNF)-alpha":[24],"has":[25],"been":[26],"suggested":[27],"to":[28,46,112],"have":[29],"possible":[31],"role":[32],"the":[34,48,77,89,117,126,148,166,176,226,238],"mechanism":[35],"underlying":[36],"acantholysis.":[37],"OBJECTIVES:":[38],"This":[39],"comparative":[40],"double-blinded":[41],"study":[42,68],"was":[43,131,142,156,170,198,246],"carried":[44],"out":[45],"estimate":[47],"use":[49,217],"of":[50,97,154,162,179,218,228,241],"both":[51,125,160],"sulfasalazine":[52],"(SSZ)":[53],"and":[54,83,85,99,120,129,194,220,233,243],"pentoxifylline":[55],"(PTX)":[56],"(low-cost":[57],"anti-TNF":[58],"drugs)":[59],"as":[60,106,222],"an":[61],"adjuvant":[62,223],"therapy":[63,224],"for":[64,136,146],"PV.":[65],"METHODS:":[66],"The":[67,151,216],"included":[69,105],"64":[70],"patients":[71,75,87,163,182,205],"with":[72,187,210,248],"PV:":[73],"42":[74],"received":[76,94],"full":[78],"treatment":[79,123,227],"regimen":[80,91],"(with":[81],"SSZ":[82,221],"PTX)":[84],"22":[86],"followed":[88],"same":[90],"except":[92],"they":[93],"placebo":[95],"instead":[96],"PTX":[98,219],"SSZ.":[100],"Five":[101],"healthy":[102,167],"subjects":[103],"were":[104,110],"controls.":[107],"Serum":[108],"samples":[109],"taken":[111],"measure":[113],"TNF-alpha":[114,155,180],"levels":[115,178],"control":[118],"group":[119,184,190,207,213],"before":[121],"starting":[122],"patient":[127],"groups":[128,161],"this":[130,244],"repeated":[132],"every":[133,144],"2":[134,191],"weeks":[135],"8":[137,195],"weeks;":[138],"clinical":[140,202,250],"assessment":[141],"made":[143],"week":[145],"all":[147],"patients.":[149],"RESULTS:":[150],"serum":[152,177,239],"level":[153,240],"statistically":[157,172],"higher":[158],"than":[164],"individuals.":[168],"There":[169,197],"significant":[173,201,235],"decrease":[174,236,245],"1":[185,208],"compared":[186,209],"those":[188,211],"at":[192],"6":[193],"weeks.":[196],"also":[199],"improvement":[203],"2.":[214],"CONCLUSION:":[215],"PV":[229],"induced":[230],"faster":[232],"more":[234],"TNF-alpha,":[242],"associated":[247],"rapid":[249],"improvement.":[251]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2012298247","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
